- Home
- ALLO
as 10-28-2025 12:46am EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 252.9M | IPO Year: | 2018 |
| Target Price: | $8.80 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $3.78 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | -76.84% |
| Revenue Growth (this year): | -53.64% | Revenue Growth (next year): | 100.00% |
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Oct 21 '25 | Sell | $1.26 | 36,744 | $46,168.84 | 1,276,796 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
MT Newswires
14 days ago
Allogene Therapeutics Faces Patent Infringement Challenges
Zacks
18 days ago
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Zacks
18 days ago
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
MT Newswires
18 days ago
JPMorgan Downgrades Allogene Therapeutics to Underweight From Neutral
Zacks
20 days ago
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
Zacks
20 days ago
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
Simply Wall St.
3 months ago
Allogene Therapeutics And 2 Other Promising Penny Stocks To Watch
Compare ALLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.